Abstract
The use of the clonogenic or stem-cell assay in clinical practice has demonstrated exponential growth over the past five years. An attempt will be made to outline the development of this system, including both practical and theoretical considerations. The current status of the assay in terms of its usefulness and its problems will be explored. In addition, the current data on correlations between in vitro results and clinical results will be presented. The last sections will be devoted to an analysis of one laboratory’s data on the application of this system to patients with lung cancer. For further general considerations of the cloning assay, the reader is referred to recent comprehensive reviews of the system [1–4].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Von Hoff DD, Wiesenthal L: In vitro methods to predict for patient response to chemotherapy. Adv in Pharm and Chemother 17: 133–156, 1980.
Von Hoff DD, Harris GJ, Johnson G, Glaubiger D: Initial experience with the human tumor stem cell assay system: Potential and problems. In: Cloning of Human Tumor Stem Cells. Salmon SE (ed). New York: Liss, 1980, pp 113–124.
Von Hoff DD: A human tumor stem cell system: Concepts, methodology, and application. In: Cancer and Chemotherapy III. Crooke ST and Prestayko AW (eds). Academic Press, 1981, pp 207–218.
Salmon SE, Von Hoff DD: In vitro evaluation of anti-cancer drugs with the human tumor stem cell assay. Sem in Oncol 8: 377–385, 1981.
Steel GC: Cell kinetics and cell survival. In: Medical Oncology—Medical Aspects of Malignant Disease. Bagshane KD (ed). Oxford: Blackwell Scientific Publication, 1975, pp 49–66.
Pike BL, Robinson WA: Human bone marrow colony growth in agar-gel. J Cell Physiol 76: 77–84, 1970.
Bruce WR, Meeker BE, Baleriote FA: Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst 37: 233–245, 1966.
Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197: 461–463, 1977.
Hamburger AW, Salmon SE: Primary bioassay of human myeloma stem cells. J Clin Invest 60: 846–854, 1977.
Cline MJ: In vitro test systems for anti-cancer drugs. NEJM 280:955, 1969 (editorial).
Salmon SE, Buick RM: Preparation of permanent slides of intact soft agar colony cultures of hematopoietic and tumor stem cells. Cancer Res 39–1133–1136, 1979.
Trent JM: Cytogenetic analysis of human tumor cells cloned in agar. In: Cloning of Human Tumor Stem Cells. Salmon SE (ed). New York: Liss, 1980, pp 165–177.
Von Hoff DD, Johnson GE: Secretion of tumor markers in the human tumor stem cell assay system. Proc Am Assoc Cancer Res 20–51, 1979 (abstract).
Von Hoff DD: New leads from the laboratory for treating testicular cancer. In: Proc of Recent Advances in the Treatment of Ovarian and Testicular Cancer. Noordwijkerhout, The Netherlands, Dec. 6–8, 1979, pp 81–82.
Pollard EB, Tio F, Myers JW, Clark G, Coltman CA Jr, Von Hoff DD: Utilization of a human tumor cloning system to monitor for marrow involvement with small cell carcinoma of the lung. Cancer Res 41: 1015–1020, 1981.
Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. NEJM 298: 1321–1327, 1978.
Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D and Makuch R: Association between human tumor colony-forming assay results and response of an individual patient’s tumor to chemotherapy. Am J Med 70: 1027–1032, 1981.
Von Hoff DD, Wiesenthal LM, Ihde DC, Mathews MJ, Layard M, Makuch R: Growth in lung cancer colonies from bronchoscopy washings. Cancer 48: 400–403, 1981.
Callahan SK, Von Hoff DD: Growth of oat cell carcinoma of the lung in the human tumor cloning assay. Third Conference on Human Tumor Cloning, January 10–12, 1982, Tucson, Az., p 28 (abstract).
Von Hoff DD, Clark GM, Callahan SK, Livingston R: Southwest Oncology Group Trial of mitoxantrone in patients with refractory small cell cancer of the lung. Cancer Treat Rep (in press).
Dombernowsky P, Sorensen J, Aisner J, Hansen HH: Cis-dichlorodiammineplatinum (II) in small cell anaplastic bronchogenic carcinoma: A Phase II study. Cancer Treat Rep 63: 543–545, 1979.
Sierocki JS, Hicaris BS, Hopfan S, Martini N, Breton D, Golbey RB, Wittes RE: Cis-dichlorodiammineplatinum (II) and VP-16–213: An active induction regimen for small cell cancer of the lung. Cancer Treat Rep 63: 1593–1597, 1979.
Eagen RT, Frytak S, Nichols WC, Ingle JN, Creagen CT, Kvois LK: Cyclophosphamide and VP-16–213 with or without Cisplatin in squamous cell and small cell lung cancers. Cancer Treat Rep 65: 453–458, 1981.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Martinus Nijhoff Publishers, Boston
About this chapter
Cite this chapter
Callahan, S.K., Coltman, C.A., Kitten, C., Von Hoff, D.D. (1983). Tumor Cloning Assay: Application and Potential Usefulness in Lung Cancer Management. In: Greco, F.A. (eds) Biology and Management of Lung Cancer. Cancer Treatment and Research, vol 11. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-3849-9_4
Download citation
DOI: https://doi.org/10.1007/978-1-4613-3849-9_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-3851-2
Online ISBN: 978-1-4613-3849-9
eBook Packages: Springer Book Archive